Trinity Biotech plc (TRIB)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $4.96M
Last updated: Nov 17, 2026 at 4:15 PM ET
Trinity Biotech plc (TRIB) Stock Chart
Trinity Biotech (TRIB) has a latest price of $6.01 on Nov 17, 2026, 88.6% below its 52-week high of $52.50. Its price fell 77.2% over the past 12 months. The month-end price fell 99.4% over the 10 years through Oct 2026, a compound annual decline of 39.9%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $1,039.04 in Dec 2016 and its lowest $6.26 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart TRIB with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for TRIB.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 45.4%, and over 6 months it fell 64.5%. The month-end price fell 91.0% over the 3 years through Oct 2026, a compound annual decline of 55.1%.
| Period | Change |
|---|---|
| 1 month | -26.6% |
| 3 months | -45.4% |
| 6 months | -64.5% |
| 12 months | -77.2% |
| 12 months, with dividends | -77.2% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -91.0% | -55.1% |
| 5 years | -98.0% | -54.2% |
| 10 years | -99.4% | -39.9% |
Price by Year
Its best calendar year was 2020, when the price rose 269.9%, and its weakest was 2021, when it fell 62.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $6.26 | -73.6% |
| 2025 | $23.75 | -10.1% |
| 2024 | $26.43 | -59.0% |
| 2023 | $64.41 | -56.7% |
| 2022 | $148.65 | -30.8% |
| 2021 | $214.71 | -62.5% |
| 2020 | $572.07 | +269.9% |
| 2019 | $154.65 | -55.0% |
| 2018 | $343.84 | -55.1% |
| 2017 | $765.77 | -26.3% |
Trading Range
The price is 11.5% below its 50-day average of $6.79 and 58.0% below its 200-day average of $14.31.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $6.01 | |
| 52-week high | $52.50 | -88.6% |
| 52-week low | $5.00 | +20.2% |
| 50-day average | $6.79 | -11.5% |
| 200-day average | $14.31 | -58.0% |
Price Risk
Over 3 years, its largest fall from a peak was 94.9%.
| Measure | Value |
|---|---|
| 1-year beta | 1.74 |
| Largest fall, 1 year | -86.1% |
| Largest fall, 3 years | -94.9% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About TRIB
What is TRIB's 1-year price change?
Trinity Biotech's price fell 77.2% over the past 12 months. With dividends included, the 12-month total return was -77.2%.
What is TRIB's 5-year price change?
Trinity Biotech's month-end price fell 98.0% over the 5 years through Oct 2026, a compound annual decline of 54.2%. These figures leave out dividends.
What is TRIB's 52-week high and low?
Trinity Biotech's 52-week high is $52.50 and its 52-week low is $5.00. Its latest price of $6.01 on Nov 17, 2026 is 88.6% below the high.
What is TRIB's beta?
Trinity Biotech's 1-year beta against the S&P 500 is 1.74, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 86.1%.
Is the TRIB chart free?
Yes. Advanced Charting for TRIB is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
TRIB pages: Overview, Charting, Earnings, Financials, Statistics, Competitors